缺血性心肌病与能量代谢研究进展

doi:10.12066/j.issn.1007-2861.2135

上海大学学报(自然科学版) ›› 2019, Vol. 25 ›› Issue (3): 357-364.doi: 10.12066/j.issn.1007-2861.2135

所属专题：精准与转化医学

• • 下一篇

缺血性心肌病与能量代谢研究进展

张剑姝, 徐明()

北京大学第三医院心内科,血管医学研究所,国家卫生健康委心血管分子生物学与调节肽重点实验室,分子心血管学教育部重点实验室,心血管受体研究北京市重点实验室,北京100191

收稿日期:2019-04-10 出版日期:2019-06-30 发布日期:2019-06-24
通讯作者: 徐明 E-mail:xuminghi@bjmu.edu.cn
作者简介:徐明,研究员,国家自然科学基金杰出青年科学基金获得者。
北京大学心血管内科学学系副主任, 分子心血管教育部重点实验室副主任, 天然药物及仿生药物国家重点实验室PI, 国家自然科学基金杰出青年科学基金获得者.1996 年毕业于北京医科大学临床医疗系. 2001 年于日本名古屋大学获得博士学位. 2001 年至今在北京大学第三医院心内科、血管医学研究所工作, 历任博士后、助理研究员、副研究员和研究员. 目前兼任国际病理生理学会理事, 国际心脏病研究会(ISHR) 中国分会秘书、执委会常委, 中国病理生理学会心血管专业委员会副主任委员. 近年发表SCI 论文31 篇, 他引600 余次, 其中以通信或第一作者(含共同)在Circulation Research 等期刊发表论文15 篇, 获国家发明专利授权3 项. 作为课题负责人主持包括国家自然科学基金等7 项基金. 2007 年获中国药理学会Servier 青年药理学工作者奖, 2009 年获中国生理学会张锡钧基金优秀论文二等奖, 2014 年获姜必宁奖-杰出青年心脏论文奖. 2017 年作为第三完成人获国家自然科学奖二等奖.
基金资助:
国家重点研发计划资助项目(2018YFC1312700);国家重点研发计划资助项目(2018YFC1312701);国家自然科学基金资助项目(81625001)

Research Progress on ischemic heart disease and energy metabolism

Zhang Jianshu, Xu Ming()

Beijing Key Laboratory of Cardiovascular Receptors Research. Beijing 100191, China.Ischemia heart disease changes in cardiac energy metabolism, which contributes to contractile dysfunction and a decrease in cardiac efficiency. Specific metabolic changes include a relative increase in cardiac fatty acid oxidation rates and an uncoupling of glycolysis from glucose oxidation. Recent evidence suggests that therapeutically regulating cardiac energy metabolism by reducing fatty acid oxidation and/or increasing glucose oxidation can improve cardiac function of the ischaemic heart. With the development of metabolomics technology, the detection methods and mechanisms of early metabolites for ischemic cardiomyopathy are further explored. we review the change of energy metabolic which contributing to cardiac dysfunction, and then it explores the potential for targeting treatment ischemic heart disease through metabolic pathway.

Received:2019-04-10 Online:2019-06-30 Published:2019-06-24
Contact: Ming Xu E-mail:xuminghi@bjmu.edu.cn

摘要/Abstract

摘要：

缺血性心肌病伴随着心脏能量代谢的变化,这些变化主要为脂肪酸氧化速率增加和（或）葡萄糖氧化途径中糖酵解减少。通过减少脂肪酸氧化或者增加葡萄糖氧化的方式干预能量代谢,能够改善缺血性心肌病的病理变化和心脏功能。随着代谢组学检测技术的发展,针对缺血性心肌病进行早期代谢产物检测手段和机制探索方式更加多样,丰富了目前对缺血性心肌病代谢变化的认知。同时,了解并分析缺血性心肌病的代谢变化为缺血性心肌病的创新药物研发提供新线索。本文系统介绍了缺血性心脏病中三大营养物质能量代谢变化,干预不同能量变化在心脏功能障碍中的作用,并探讨通过代谢手段治疗缺血性心脏疾病的可能性。

关键词: 缺血性心肌病, 脂肪酸氧化, 代谢

Abstract:

Ischemia heart disease is often accompanied by cardiac energy metabolism, which is reflected in contractile dysfunction and a decrease in cardiac efficiency. Specific metabolic changes include a relative increase in cardiac fatty acid oxidation rates and an uncoupling of glycolysis from glucose oxidation. Recent evidence suggests that therapeutically regulating cardiac energy metabolism by reducing fatty acid oxidation and/or increasing glucose oxidation can improve cardiac function of the ischemic heart. With the development of metabolomics technology, the detection methods and mechanisms of early metabolites for ischemic cardiomyopathy are further explored. This paper first discusses systematically the change of energy metabolic which contributes to cardiac dysfunction, and then it explores the potential for targeting treatment ischemic heart disease through metabolic pathway.

Key words: Key Words：Ischemia heart disease, fatty acid oxidation, metabolism

中图分类号:

R541

张剑姝, 徐明. 缺血性心肌病与能量代谢研究进展[J]. 上海大学学报(自然科学版), 2019, 25(3): 357-364.

Zhang Jianshu, Xu Ming . Research Progress on ischemic heart disease and energy metabolism[J]. Journal of Shanghai University（Natural Science Edition）, 2019, 25(3): 357-364.

参考文献 42

[1]	Fillmore N, Levasseur J L, Fukushima A , et al. Uncoupling of glycolysis from glucose oxidation accompanies the development of heart failure with preserved ejection fraction[J]. Mol Med, 2018,24(1):3. doi: 10.1186/s10020-018-0005-x pmid: 30134787
[2]	Fillmore N, Mori J, Lopaschuk G D . Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy[J]. Br J Pharmacol, 2014,171(8):2080-2090. doi: 10.1111/bph.12475 pmid: 24147975
[3]	Stanley W C, Recchia F A, Lopaschuk G D . Myocardial substrate metabolism in the normal and failing heart. Physiol Rev, 2005,85(3):1093-1129.
[4]	McGarrah R W, Crown S B, Zhang G F , et al. Cardiovascular metabolomics[J]. Circ Res, 2018,122(9):1238-1258. doi: 10.1161/CIRCRESAHA.117.311002 pmid: 29700070
[5]	Lopaschuk G D, Ussher J R, Folmes C D , et al. Myocardial fatty acid metabolism in health and disease[J]. Physiol Rev, 2010,90(1):207-258. doi: 10.1152/physrev.00015.2009 pmid: 20086077
[6]	Chouchani E T, Pell V R, Gaude E , et al. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS[J]. Nature, 2014,515(7527):431-435. doi: 10.1038/nature13909
[7]	Yue T L, Bao W, Jucker B M , et al. Activation of peroxisome proliferator-activated receptor-alpha protects the heart from ischemia/reperfusion injury[J]. Circulation, 2003,108(19):2393-2399. doi: 10.1161/01.CIR.0000093187.42015.6C pmid: 14557369
[8]	Liu Z, Chen J M, Huang H , et al. The protective effect of trimetazidine on myocardial ischemia/reperfusion injury through activating AMPK and ERK signaling pathway[J]. Metabolism, 2016,65(3):122-130. doi: 10.1016/j.metabol.2015.10.022 pmid: 26892523
[9]	Killalea S M, Krum H . Systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease[J]. Am J Cardiovasc Drugs, 2001,1(3):193-204. doi: 10.2165/00129784-200101030-00005 pmid: 14728034
[10]	Dyck J R, Cheng J F, Stanley W C , et al. Malonyl coenzyme a decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation[J]. Circ Res, 2004,94(9):e78-e84. doi: 10.1161/01.RES.0000129255.19569.8f pmid: 15105298
[11]	Sun W, Liu Q, Leng J , et al. The role of Pyruvate Dehydrogenase Complex in cardiovascular diseases[J]. Life Sci, 2015,121:97-103. doi: 10.1016/j.lfs.2014.11.030 pmid: 25498896
[12]	Li X, Liu J, Hu H , et al. Dichloroacetate ameliorates cardiac dysfunction caused by ischemic insults through AMPK signal pathway-not only shifts metabolism[J]. Toxicol Sci, 2019,167(2):604-617. doi: 10.1093/toxsci/kfy272 pmid: 30371859
[13]	Ussher J R, Wang W, Gandhi M , et al. Stimulation of glucose oxidation protects against acute myocardial infarction and reperfusion injury[J]. Cardiovasc Res, 2012,94(2):359-369. doi: 10.1093/cvr/cvs129
[14]	Folmes C D, Sowah D, Clanachan A S , et al. High rates of residual fatty acid oxidation during mild ischemia decrease cardiac work and efficiency[J]. J Mol Cell Cardiol, 2009,47(1):142-148. doi: 10.1016/j.yjmcc.2009.03.005 pmid: 19303418
[15]	Hooper L, Martin N, Abdelhamid A , et al. Reduction in saturated fat intake for cardiovascular disease[J]. Cochrane Database Syst Rev, 2015 (6): CD011737. doi: 10.1002/14651858.CD011737 pmid: 26068959
[16]	Wang D D, Li Y, Chiuve S E , et al. Association of specific dietary fats with total and cause-specific mortality[J]. JAMA Intern Med, 2016,176(8):1134-1145. doi: 10.1001/jamainternmed.2016.2417 pmid: 27379574
[17]	Gonzalez-Rodriguez A, Mayoral R, Agra N , et al. Impaired autophagic flux is associated with increased endoplasmic reticulum stress during the development of NAFLD[J]. Cell Death Dis, 2014,5:e1179. doi: 10.1038/cddis.2014.162 pmid: 24743734
[18]	van de Weijer T, Schrauwen-Hinderling V B, Schrauwen P . Lipotoxicity in type 2 diabetic cardiomyopathy[J]. Cardiovasc Res, 2011,92(1):10-18. doi: 10.1093/cvr/cvr212
[19]	Holland W L, Summers S A . Strong heart, low ceramides[J]. Diabetes, 2018,67(8):1457-1460. doi: 10.2337/dbi18-0018 pmid: 30030288
[20]	Laaksonen R, Ekroos K, Sysi-Aho M , et al. Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol[J]. Eur Heart J, 2016,37(25):1967-1976. doi: 10.1093/eurheartj/ehw148 pmid: 27125947
[21]	Souza-Mello V . Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease[J]. World J Hepatol, 2015,7(8):1012-1019. doi: 10.4254/wjh.v7.i8.1012 pmid: 26052390
[22]	Dezsi C A . Trimetazidine in practice: review of the clinical and experimental evidence[J]. Am J Ther, 2016,23(3):e871-e879. doi: 10.1097/MJT.0000000000000180 pmid: 25756467
[23]	Danchin N, Marzilli M, Parkhomenko A , et al. Efficacy comparison of trimetazidine with therapeutic alternatives in stable angina pectoris: a network meta-analysis[J]. Cardiology, 2011,120(2):59-72. doi: 10.1159/000332369
[24]	Ciapponi A, Pizarro R, Harrison J. Trimetazidine for stable angina [J]. Cochrane Database Syst Rev, 2005 (4): CD003614. doi: 10.1002/14651858.CD003614.pub2 pmid: 16235330
[25]	Zhao Q, Cui Z, Zheng Y , et al. Fenofibrate protects against acute myocardial I/R injury in rat by suppressing mitochondrial apoptosis as decreasing cleaved caspase-9 activation[J]. Cancer Biomark, 2017,19(4):455-463. doi: 10.3233/CBM-170572 pmid: 28582851
[26]	Bukhari I A, Almotrefi A A, Mohamed O Y , et al. Protective effect of fenofibrate against ischemia-/reperfusion-induced cardiac arrhythmias in isolated rat hearts[J]. Fundam Clin Pharmacol, 2018,32(2):141-146. doi: 10.1111/fcp.12342 pmid: 29290096
[27]	Lam V H, Zhang L, Huqi A , et al. Activating PPARalpha prevents post-ischemic contractile dysfunction in hypertrophied neonatal hearts[J]. Circ Res, 2015,117(1):41-51. doi: 10.1161/CIRCRESAHA.117.306585 pmid: 25977309
[28]	Jaswal J S, Keung W, Wang W , et al. Targeting fatty acid and carbohydrate oxidation--a novel therapeutic intervention in the ischemic and failing heart[J]. Biochim Biophys Acta, 2011,1813(7):1333-1350. doi: 10.1016/j.bbamcr.2011.01.015 pmid: 21256164
[29]	Yamauchi T, Nio Y, Maki T , et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions[J]. Nature Medicine, 2007,13:332. doi: 10.1038/nm1557 pmid: 17268472
[30]	Knottnerus S J G, Bleeker J C, Wust R C I , et al. Disorders of mitochondrial long-chain fatty acid oxidation and the carnitine shuttle[J]. Rev Endocr Metab Disord, 2018,19(1):93-106. doi: 10.1007/s11154-018-9448-1 pmid: 29926323
[31]	Mallet R T, Squires J E, Bhatia S , et al. Pyruvate restores contractile function and antioxidant defenses of hydrogen peroxide-challenged myocardium[J]. Journal of Molecular and Cellular Cardiology, 2002,34(9):1173-1184. doi: 10.1006/jmcc.2002.2050
[32]	Wolff A A, Rotmensch H H, Stanley W C , et al. Metabolic approaches to the treatment of ischemic heart disease: the clinicians' perspective[J]. Heart Failure Reviews, 2002,7(2):187-203. doi: 10.1023/A:1015384710373
[33]	Ussher J R, Koves T R, Jaswal J S , et al. Insulin-stimulated cardiac glucose oxidation is increased in high-fat diet-induced obese mice lacking Malonyl CoA Decarboxylase[J]. Diabetes, 2009,58(8):1766-1775. doi: 10.2337/db09-0011 pmid: 19478144
[34]	Mdaki K S, Larsen T D, Wachal A L , et al. Maternal high-fat diet impairs cardiac function in offspring of diabetic pregnancy through metabolic stress and mitochondrial dysfunction[J]. Am J Physiol Heart Circ Physiol, 2016,310(6):H681-H692. doi: 10.1152/ajpheart.00795.2015 pmid: 26801311
[35]	Vlassara H, Uribarri J . Advanced glycation end products (AGE) and diabetes: cause, effect, or both?[J]. Curr Diab Rep, 2014,14(1):453. doi: 10.1007/s11892-013-0453-1 pmid: 24292971
[36]	Mizushima N, Yoshimori T, Ohsumi Y . The role of Atg proteins in autophagosome formation[J]. Annu Rev Cell Dev Biol, 2011,27:107-132. doi: 10.1146/annurev-cellbio-092910-154005 pmid: 21801009
[37]	Ruiz-Canela M, Toledo E, Clish C B , et al. Plasma branched-chain amino acids and incident cardiovascular disease in the PREDIMED trial[J]. Clinical Chemistry, 2016,62(4):582-592. doi: 10.1373/clinchem.2015.251710 pmid: 26888892
[38]	Lu G, Sun H, She P , et al. Protein phosphatase 2Cm is a critical regulator of branched-chain amino acid catabolism in mice and cultured cells[J]. J Clin Invest, 2009,119(6):1678-1687. doi: 10.1172/JCI38151 pmid: 19411760
[39]	Newgard C B . Interplay between lipids and branched-chain amino acids in development of insulin resistance[J]. Cell Metab, 2012,15(5):606-614. doi: 10.1016/j.cmet.2012.01.024
[40]	Crowe M J, Weatherson J N, Bowden B F . Effects of dietary leucine supplementation on exercise performance[J]. Eur J Appl Physiol, 2006,97(6):664-672. doi: 10.1007/s00421-005-0036-1 pmid: 16265600
[41]	D'Antona G, Ragni M, Cardile A, et al. Branched-chain amino acid supplementation promotes survival and supports cardiac and skeletal muscle mitochondrial biogenesis in middle-aged mice[J]. Cell Metab, 2010,12(4):362-372. doi: 10.1016/j.cmet.2010.08.016
[42]	Li T, Zhang Z, Kolwicz S C, Jr ., et al. Defective branched-chain amino acid catabolism disrupts glucose metabolism and sensitizes the heart to ischemia-reperfusion injury[J]. Cell Metab, 2017,25(2):374-385. doi: 10.1016/j.cmet.2016.11.005 pmid: 28178567

缺血性心肌病与能量代谢研究进展

Research Progress on ischemic heart disease and energy metabolism

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 42

相关文章 4

编辑推荐

Metrics

本文评价

[1]	李玉峰, 刘欣杰, 张新宇. 1-氯-3-丁烯-2-醇的细胞遗传毒性[J]. 上海大学学报(自然科学版), 2019, 25(4): 558-565.
[2]	后文琳, 潘雯, 付思艺, 宋美怡, 王菲. 小鼠非酒精性脂肪性肝炎中线粒体功能的障碍[J]. 上海大学学报(自然科学版), 2019, 25(1): 1-9.
[3]	刘柏良, 张新宇. 1-氯-3-丁烯-2-酮与N-乙酰半胱氨酸的反应[J]. 上海大学学报(自然科学版), 2018, 24(1): 74-82.
[4]	任国发1 2 于志强2 孙延枫1 马盛韬2 罗湘凡1 盛国英1 2 傅家谟1 2. 电子垃圾拆解工人血清中多溴联苯醚代谢产物的识别及其特征[J]. 上海大学学报(自然科学版), 2010, 16(5): 441-446.